thymosin beta-4 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-06-08. Anything still debated is marked as such rather than presented as settled.
Whether the free 28-residue peptide circulates in human tissue remains debated. The best-documented human source is prothymosin alpha, a larger acidic protein that carries the sequence at its N-terminus. Reports of measurable peptide levels in serum and lymphoid tissue exist, yet some of that signal may come from cross-reacting fragments or from the parent protein. Most reviews therefore treat prothymosin alpha as the established human molecule and describe independent circulation of the small peptide as an unresolved question.
Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.
Thymosin alpha-1 is a synthetic 28-amino-acid peptide whose sequence was first identified in extracts of bovine thymus tissue during the 1970s. The chain carries an acetyl group on its N-terminal serine. Its acidic residue content is high, which produces strong water solubility and an isoelectric point well below neutrality. Material supplied for laboratory and clinical use is manufactured by solid-phase peptide synthesis rather than purified from animal tissue. Different salt forms, such as the acetate, alter the counter-ion content without changing the peptide backbone.
胸腺素α1对免疫系统的影响涉及多种细胞类型。研究表明，它可促进未成熟T细胞向成熟T细胞分化，并增强T细胞对抗原刺激的增殖反应。树突状细胞在Tα1存在下表达更高水平的共刺激分子，从而更有效地呈递抗原。此外，自然杀伤细胞的活性也观察到上升。这些效应并非直接杀伤病原体，而是调节宿主免疫应答的强度与方向。
在信号层面，Tα1可能通过Toll样受体等模式识别受体发挥作用。部分实验显示，它能激活髓样分化因子88依赖的通路，进而促进核因子κB进入细胞核。这导致白细胞介素2、干扰素γ和白细胞介素12等细胞因子的转录增加。这些细胞因子偏向辅助性T细胞1型应答，有助于细胞免疫。然而，具体受体和结合位点尚未完全确定，不同实验模型的结果存在差异。
临床研究将Tα1用于慢性病毒感染、肿瘤辅助治疗和疫苗佐剂等场景。部分试验报告了免疫学指标改善，但临床终点获益在不同研究中并不一致。系统综述指出，研究间在人群、剂量和联合方案上差异较大，难以汇总结论。因此，Tα1的确切临床地位仍属开放问题，需要更多高质量随机对照试验来澄清。其机制研究也需从体外实验向体内模型推进。
| Property | Value | Notes |
|---|---|---|
| Amino acid length | 28 residues | Single chain with an acetylated N-terminus |
| Molecular mass | Approximately 3,108 Da | Small shifts occur with counter-ion and water content |
| Isoelectric point | Around 3.5 | Low value follows from the many acidic residues |
| Parent molecule | N-terminal region of prothymosin alpha | Free circulating form in humans is not firmly established |
| Common synonyms | Thymalfasin; T alpha 1 | Older literature also uses the full spelled-out form |
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
Thymosin alpha 1 is a 28-amino-acid peptide first isolated from thymosin fraction 5, a bovine thymic extract. Its sequence begins with an acetylated serine residue and carries a high proportion of acidic residues, so the molecule has a net negative charge near neutral pH. Despite the shared name, it is unrelated in sequence to the thymosin beta family. Synthetic material prepared by solid-phase peptide synthesis is identical in sequence to the natural peptide.
Several names appear in the literature for this peptide, including thymalfasin and the abbreviation T-alpha-1. Naming conventions differ among research articles, regulatory documents, and supplier catalogs, which complicates literature searches. Both synthetic and recombinant production routes yield a peptide with the same 28-residue sequence as the thymic isolate. Because the thymosin label also covers unrelated peptides, sources should be compared by sequence rather than by name alone.
The molecule consists of 28 amino acid residues with an acetyl group attached to the N-terminal serine. Its sequence is acidic overall, with several glutamic and aspartic acid residues distributed along the chain and no cysteine, so disulfide bridges do not form. The peptide carries a net negative charge at physiological pH. Because the N-terminus is blocked, the intact molecule resists degradation by many aminopeptidases, which contributes to its stability in biological fluids.
The peptide is generated in cells by cleavage of prothymosin alpha, a larger acidic protein encoded by the PTMA gene. Prothymosin alpha is expressed in many tissues, not only in the thymus, and its functions include nuclear roles in chromatin-related processes. The 28-residue fragment corresponds to the N-terminal portion of that precursor. How the cleavage occurs and how the fragment's concentration is regulated remain open questions; circulating amounts are small and difficult to measure reliably with routine assays.
Some other researchers were more optimistic. AI pioneer Jürgen Schmidhuber did not sign the joint statement, emphasising that in 95% of all cases, AI research is about making "human lives longer and healthier and easier." While the tools that are now being used to improve lives can also be used by bad actors, "they can also be used against the bad actors." Andrew Ng also argued that "it's a mistake to fall for the doomsday hype on AI—and that regulators who do will only benefit vested interests." Yann LeCun, a Turing Award winner, disagreed with the idea that AI will subordinate humans "simply because they are smarter, let alone destroy [us]", "scoff[ing] at his peers' dystopian scenarios of supercharged misinformation and even, eventually, human extinction." In contrast, he claimed that "intelligent machines will usher in a new renaissance for humanity, a new era of enlightenment." In the early 2010s, experts argued that the risks are too distant in the future to warrant research or that humans will be valuable from the perspective of a superintelligent machine. However, after 2016, the study of current and future risks and possible solutions became a serious area of research. Some have argued that concerns about existential risks of AI could draw attention away from other AI risks.
Kipa-Williams added that it meant a lot to them and believed viewers back home would be able to connect with their characters. Kipa-Williams said Ari moves to Summer Bay as he wants a quieter life. He explained "Ari is going through quite a change – he's decided he doesn't want to be part of his old life any more. He's made a strong decision to be another way, and he's guiding his sister-in-law and nephew away from their old lives, too. He feels a huge weight of responsibility to provide for his family." Discussing the family's fictional backstory, Kipa-Williams revealed that the Paratas were run out of their old town and they worry that it could happen again. He also said that Ari has become used to seeing violence, such as that used in the hospital siege, so it does not bother him as much. After his involvement in the hospital siege, Ari quickly leaves the scene when he notices the press have turned up. He is also keen to find his nephew Nikau. Rachel Lucas of What's on TV observed that there seemed to be some "bad blood" between the pair, and Kipa-Williams told her that Nikau blames Ari for a situation that occurred in their past. He also told Lucas: "You don't really find out about the family's secret straight away. You start to see the complexities, how close they are and that they do love each other, but that it's messed up with past trauma." Ari, Nikau and Gemma are soon reunited, but his brother Tane does not immediately join the family. It becomes clear that Tane is an "outcast", as he earns his money through illegitimate means, which Ari disapproves of.
== Further reading == Theravada Walpola Rahula (1974), What the Buddha Taught P. A. Payutto, Dependent Origination: The Buddhist Law of Conditionality (translation for the fourth chapter of P. A. Payutto's Buddhadhamma) Ajahn Sucitto (2010). Turning the Wheel of Truth: Commentary on the Buddha's First Teaching. Shambhala. (pages 61–76) Jackson, Peter A. (2003), Buddhadasa. Theravada Buddhism and Modernist reform in Thailand, Silkworm Books Ajahn Amaro (2021), Catastrophe/Apostrophe: The Buddha's Teachings on Dependent Origination/Cessation, Amaravati Publications Tibetan Buddhism Chogyam Trungpa (1972). "Karma and Rebirth: The Twelve Nidanas, by Chogyam Trungpa Rinpoche." Karma and the Twelve Nidanas, A Sourcebook for the Shambhala School of Buddhist Studies. Vajradhatu Publications. Dalai Lama (1992). The Meaning of Life, translated and edited by Jeffrey Hopkins, Boston: Wisdom. Geshe Sonam Rinchen (2006). How Karma Works: The Twelve Links of Dependent Arising. Snow Lion Khandro Rinpoche (2003). This Precious Life. Shambala Thrangu Rinpoche (2001). The Twelve Links of Interdependent Origination. Nama Buddha Publications. Scholarly Frauwallner, Erich (1973), "Chapter 5. The Buddha and the Jina", History of Indian Philosophy: The philosophy of the Veda and of the epic. The Buddha and the Jina. The Sāmkhya and the classical Yoga-system, Motilal Banarsidass Bucknell, Roderick S.
Sources: en.wikipedia.org
=== Final tour and death in New York === Thomas left Laugharne on 9 October 1953 on the first leg of his fourth trip to America. He called on his mother, Florence, to say goodbye: "He always felt that he had to get out from this country because of his chest being so bad." Thomas had suffered from chest problems for most of his life, though they began in earnest soon after he moved in May 1949 to the Boat House at Laugharne—the "bronchial heronry", as he called it. Within weeks of moving in, he visited a local doctor, who prescribed medicine for both his chest and throat. While waiting in London before his flight, Thomas stayed with the comedian Harry Locke and worked on Under Milk Wood. Locke noted that Thomas was having trouble with his chest, "terrible" coughing fits that made him go purple in the face. He was also using an inhaler to help his breathing. There were reports, too, that Thomas was also having blackouts. His visit to the BBC producer Philip Burton, a few days before he left for New York, was interrupted by a blackout. On his last night in London, he had another in the company of his fellow poet Louis MacNeice. Thomas arrived in New York on 20 October 1953 to undertake further performances of Under Milk Wood, organised by John Brinnin, his American agent and Director of the Poetry Centre. Brinnin did not travel to New York but remained in Boston to write. He handed responsibility to his assistant, Liz Reitell. She met Thomas at Idlewild Airport and was shocked at his appearance.
, in order to characterize the geometry. This correction factor, also often referred to as the geometric shape factor, is given by empirically determined series and accounts for the type and geometry of the crack or notch. We thus have:
=== Marketing controversy === In 2001, Eli Lilly's chairman, president and CEO, Sidney Taurel, told shareholders: "No medicine better symbolizes our mission than Xigris," calling it "one of our industry's genuine breakthroughs." Xigris was designed to fight sepsis, a condition that kills more than 200,000 Americans annually. It was the only approved drug for sepsis, and it costs $8,000 to treat a single patient. Lilly hoped it would be a blockbuster, with sales of at least a billion dollars a year. But, after five years on the market, sales were only $200 million. Eli Lilly used the Belsito & Company PR firm in a marketing campaign to promote Xigris. A report accused the company of initiating false reports of a shortage of the drug to boost sales. Belsito and Company spread the word that the drug was being "rationed" and physicians were being 'systematically forced' to decide who would live and who would die. As part of this effort, Lilly provided a group of physicians and bioethicists with a $1.8 million grant to form the Values, Ethics, and Rationing in Critical Care (VERICC) Task Force, purportedly to address ethical issues raised by rationing in the intensive care unit. Finally, the Surviving Sepsis Campaign was established, in theory to raise awareness of severe sepsis and generate momentum toward the development of treatment guidelines. This marketing campaign was especially troublesome because Xigris has been linked to increased risk of serious bleeding in patients who used it as well as other concerns.
Sources: en.wikipedia.org
At the start of the Meiji era, Japanese metalwork was almost totally unknown outside the country, unlike lacquer and porcelain which had previously been exported. Metalwork was connected to Buddhist practice, for example in the use of bronze for temple bells and incense cauldrons, so there were fewer opportunities for metalworkers once Buddhism was displaced as the state religion. International exhibitions brought Japanese cast bronze to a new foreign audience, attracting strong praise. Suzuki Chokichi, a leading producer of cast bronze for international exhibition, became director of the Kiritsu Kosho Kaisha from 1874 to the company's dissolution in 1891. In 1896 he was appointed Artist to the Imperial Household. The works of Chokichi and his contemporaries took inspiration from late Edo period carvings and prints, combining and sometimes exaggerating traditional design elements in new ways to appeal to the export market. The past history of samurai weaponry equipped Japanese metalworkers to create metallic finishes in a wide range of colors. By combining and finishing copper, silver and gold in different proportions, they created specialized alloys including shakudō and shibuichi. With this variety of alloys and finishes, an artist could give the impression of full-color decoration. Some of these metalworkers were appointed Artists to the Imperial Household, including Kano Natsuo, Unno Shomin, Namekawa Sadakatsu, and Jomi Eisuke II.
=== Neurosurgical research and innovations === Maroon has conducted extensive research into neurotrauma, brain tumors, and diseases of the spine, which led to many innovative techniques for diagnosing and treating these disorders. Maroon was the first to publish on the use of ultrasound to detect venous air emboli (1968). Maroon et al. were the first to publish on the use of ultrasound to detect air in patients during neurosurgical procedures (1969) and to assess ophthalmic artery reversal of flow, indicating a thrombosis of the carotid artery (1969). Maroon et al. published the simplified instrumentation for performing microvascular surgery in 1973, and in 1975, they pioneered the microsurgical approach to intra-orbital tumors. In 1977, they pioneered the use of CT scanning as a guidance system for performing intracranial biopsy. In the same year, Maroon published the first paper on "burning hands" syndrome related to sports-related spinal cord injuries in JAMA. In 1982, Maroon et al. pioneered the radical orbital decompression procedure for severe dysthyroid exophthalmos. In 1985, they were the first to compare microsurgical disc removal with chemonucleolysis and in 1986, they were the first to use a carbon dioxide laser in the management of lymphangiomas of the orbit. That year, Maroon et al. were among the first to describe their surgery outcomes with microlumbar discectomy. In 1987, Maroon and Onik introduced percutaneous automated discectomy as a new minimally invasive way to remove lumbar discs and subsequently published extensively on this technique.
== Legal status == As of March 2022, the European Commission has taken new measures to control the psychoactive substance of 3-CMC. This decision is based on a risk assessment conducted by the EU Drugs Agency (EMCDDA) in November 2021. Since 3-CMC was prohibited in China (October 2015), it was found that most of the production was manufactured in India and little of the substance supply originates from inside Europe. Several European countries were ahead of the European Commission report by (generically) controlling the substance. Nowadays, in almost all countries 3-CMC is prohibited.
Sources: en.wikipedia.org
It is usually described as an immunomodulatory peptide rather than a classic circulating hormone. No endocrine gland is known to release it as a primary secretory product, and its measured presence in blood is not firmly established.
Prothymosin alpha is a much larger acidic protein, roughly 111 to 113 residues long, and the thymosin alpha-1 sequence matches its N-terminal region. The small peptide is therefore best understood as a fragment of that parent protein rather than a separate gene product.
Trials and clinical reports have examined chronic hepatitis B and C, use as a vaccine adjuvant, and supportive treatment in some immunodeficiency and oncology settings. Results vary by indication, and regulatory approval differs between countries.
它促进未成熟T细胞分化并增强成熟T细胞的增殖与细胞因子分泌。这些作用有助于放大抗原特异性免疫应答。